pharmaxis update21 Oct 2020 10:36
I see there is a shareholder update for pharmaxis on 30th oct - are we expecting any news re loxl2?
30 October Quarterly shareholder update and cash flow filed with ASX
4 November, 10.00am Annual general meeting - virtual meeting.
Synairgen has collaborated with Australian pharmaceutical research company Pharmaxis to develop small molecule inhibitors of LOXL2 for the treatment of fibrotic disease